Several ongoing studies are testing such ICI combinations e.g. of atezolizumab with the tyrosine kinase inhibitor (TKI) cabozantinib in recurrent GB (NCT05039281), the anti-PD-1 ezabenlimab with a HER2-CAR-NK (NK-92/5.28.z) in recurrent HER2-positive GB (NCT03383978), avelumab with a T cell vaccine against VEGFR2 (VXM01) (NCT03750071) or pembrolizumab with tumor treating fields (TTF) therapy (NCT03405792) or with the oncolytic virus lerapolturev (formerly PVSRIPO) (NCT04479241). Here, ERBB2 is linked to neoplasm.